The effect of treatment with recombinant human growth hormone (rhGH) on linear growth and adult height in children with idiopathic short stature (ISS): a systematic review and meta-analysis.

Plain-language guide to PMID 33035189 (2020): meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Key Facts

PMID: 33035189
Journal: Journal of pediatric endocrinology & metabolism : JPEM
Year: 2020
Study type: Meta-Analysis
Authors: Paltoglou G et al. (4 authors)
DOI: 10.1515/jpem-2020-0287

What This Paper Covers, in Plain Language

What It Covers

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this meta-analysis publication.

Idiopathic short stature (ISS) is a recognized, albeit a controversial indication for treatment with recombinant human growth hormone (rhGH).The objective of the present study was to conduct a systematic review of the literature and meta-analyses of selected studies about the use of rhGH in children with ISS on linear growth and adult height (AH).

Who the Included Studies Covered

The remaining 112 studies were evaluated further by assessing the full text; 21 of them fulfilled all the criteria in order to be included in the current meta-analysis.

How the Review Was Done

A systematic literature search was conducted to identify relevant studies published till February 28, 2017 in the following databases: Medline (PubMed), Scopus and Cochrane Central Registry of Controlled Trials.

After exclusion of duplicate studies, 3,609 studies were initially identified.

Of those, 3,497 studies were excluded during the process of assessing the title and/or the abstract.

What Was Measured

PubMed files the paper under topics including Body Height, Dwarfism, Growth Disorders, Human Growth Hormone and Recombinant Proteins.

Author keywords: ISS, adult height, growth hormone treatment, idiopathic short stature, meta-analysis and rhGH.

What This Means in Plain Language

This is a meta-analysis of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.